Dr. Weinblatt has received consultant fees and/or honoraria (less than $10,000 each) from Amgen, AstraZeneca, Centocor, Merck, and UCB, and (more than $10,000 each) from Abbott, Pfizer, and Roche/Genentech.
Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four–week results of an open-label, clinical practice study†
Version of Record online: 26 FEB 2013
Copyright © 2013 by the American College of Rheumatology
Arthritis Care & Research
Volume 65, Issue 3, pages 362–371, March 2013
How to Cite
Weinblatt, M. E., Kremer, J., Cush, J., Rigby, W., Teng, L. L., Devenport, J., Singh, N., Lepley, D. and Genovese, M. C. (2013), Tocilizumab as monotherapy or in combination with nonbiologic disease-modifying antirheumatic drugs: Twenty-four–week results of an open-label, clinical practice study. Arthritis Care Res, 65: 362–371. doi: 10.1002/acr.21847
ClinicalTrials.gov identifier: NCT00891020.
- Issue online: 21 FEB 2013
- Version of Record online: 26 FEB 2013
- Accepted manuscript online: 12 SEP 2012 10:56PM EST
- Manuscript Accepted: 29 AUG 2012
- Manuscript Received: 26 APR 2012
Additional Supporting Information may be found in the online version of this article.
|ACR_21847_sm_AppendixA.doc||75K||Supplementary Appendix A|
Please note: Wiley Blackwell is not responsible for the content or functionality of any supporting information supplied by the authors. Any queries (other than missing content) should be directed to the corresponding author for the article.